Skip to main content
AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)
Loading prices
Back to the NewsWire

Allsci

Published November 16, 2026 · Updated November 17, 2026

Helus' psychedelic -derived depression drug meets Phase III primary endpoint - AllSci

Read the full story at Allsci

Pharma & Biotech · Academic Institutions. Company. About · News · Newsletter · Pricing · Contact. Get started. Log in · Sign up free. © 2026 AllSci.

Surfaced by this Google Alert

  • Psychedelic biotech